Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TomaGold Borehole EM Survey Confirms Berrigan Deep Zone (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Nascent Biotech Inc (EM) NBIO

Healthcare Biotechnology
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing... see more

Recent & Breaking News (EXPM:NBIO)

Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing

GlobeNewswire January 21, 2025

Nascent Biotech Presents at the July Emerging Growth Conference

ACCESS Newswire July 30, 2024

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

ACCESS Newswire April 16, 2024

Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System

ACCESS Newswire March 19, 2024

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

ACCESS Newswire February 6, 2024

Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued

ACCESS Newswire January 9, 2024

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

ACCESS Newswire December 19, 2023

Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier

ACCESS Newswire November 29, 2023

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

ACCESS Newswire August 22, 2023

Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting

ACCESS Newswire June 7, 2023

Nascent Biotech Regains Worldwide Rights for Pritumumab

ACCESS Newswire May 26, 2023

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

ACCESS Newswire May 9, 2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval

ACCESS Newswire April 18, 2023

Nascent Announces the Completion of Its Phase1 Clinical Trials

ACCESS Newswire February 28, 2023

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

ACCESS Newswire January 25, 2023

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

ACCESS Newswire January 10, 2023

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

ACCESS Newswire December 20, 2022

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

ACCESS Newswire November 1, 2022

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

ACCESS Newswire October 4, 2022

Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

ACCESS Newswire September 13, 2022

Podcasts